

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 0704-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE 3/1/93 - 2/28/96	3. REPORT TYPE AND DATES COVERED Final Report	
4. TITLE AND SUBTITLE Novel Biopolymeric Materials			5. FUNDING NUMBERS N00014-93-1-0380 R&T 341u011	
6. AUTHOR(S) Peter G. Schultz				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Department of Chemistry University of California, Berkeley Berkeley, CA 94720			8. PERFORMING ORGANIZATION REPORT NUMBER -----	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) Office of Naval Research 800 North Quincy Street Arlington, VA 22217-5660			10. SPONSORING/MONITORING AGENCY REPORT NUMBER -----	
11. SUPPLEMENTARY NOTES			19960827 133	
12a. DISTRIBUTION/AVAILABILITY STATEMENT Distribution Unlimited			12b. DISTRIBUTION CODE	
<div style="border: 1px solid black; padding: 5px; display: inline-block;"> <p style="margin: 0;">DISTRIBUTION STATEMENT A</p> <p style="margin: 0;">Approved for public release Distribution Unlimited</p> </div>				
13. ABSTRACT (Maximum 200 words)				
<p>Efficient synthetic methods have been generated for the (i) synthesis of libraries of unnatural oligomers, (ii) methods have been developed for the generation and screening of libraries of electronic, magnetic and optical materials, (iii) miniantibodies have been generated which share some of the properties of antibodies themselves.</p>				
14. SUBJECT TERMS			15. NUMBER OF PAGES	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT U	18. SECURITY CLASSIFICATION OF THIS PAGE U	19. SECURITY CLASSIFICATION OF ABSTRACT U	20. LIMITATION OF ABSTRACT UL	

GENERAL INSTRUCTIONS FOR COMPLETING SF 298

The Report Documentation Page (RDP) is used in announcing and cataloging reports. It is important that this information be consistent with the rest of the report, particularly the cover and title page. Instructions for filling in each block of the form follow. It is important to *stay within the lines* to meet *optical scanning requirements*.

Block 1. Agency Use Only (Leave blank).

Block 2. Report Date. Full publication date including day, month, and year, if available (e.g. 1 Jan 88). Must cite at least the year.

Block 3. Type of Report and Dates Covered. State whether report is interim, final, etc. If applicable, enter inclusive report dates (e.g. 10 Jun 87 - 30 Jun 88).

Block 4. Title and Subtitle. A title is taken from the part of the report that provides the most meaningful and complete information. When a report is prepared in more than one volume, repeat the primary title, add volume number, and include subtitle for the specific volume. On classified documents enter the title classification in parentheses.

Block 5. Funding Numbers. To include contract and grant numbers; may include program element number(s), project number(s), task number(s), and work unit number(s). Use the following labels:

C - Contract	PR - Project
G - Grant	TA - Task
PE - Program Element	WU - Work Unit Accession No.

Block 6. Author(s). Name(s) of person(s) responsible for writing the report, performing the research, or credited with the content of the report. If editor or compiler, this should follow the name(s).

Block 7. Performing Organization Name(s) and Address(es). Self-explanatory.

Block 8. Performing Organization Report Number. Enter the unique alphanumeric report number(s) assigned by the organization performing the report.

Block 9. Sponsoring/Monitoring Agency Name(s) and Address(es). Self-explanatory.

Block 10. Sponsoring/Monitoring Agency Report Number. (If known)

Block 11. Supplementary Notes. Enter information not included elsewhere such as: Prepared in cooperation with...; Trans. of...; To be published in... When a report is revised, include a statement whether the new report supersedes or supplements the older report.

Block 12a. Distribution/Availability Statement. Denotes public availability or limitations. Cite any availability to the public. Enter additional limitations or special markings in all capitals (e.g. NOFORN, REL, ITAR).

DOD - See DoDD 5230.24, "Distribution Statements on Technical Documents."

DOE - See authorities.

NASA - See Handbook NHB 2200.2.

NTIS - Leave blank.

Block 12b. Distribution Code.

DOD - Leave blank.

DOE - Enter DOE distribution categories from the Standard Distribution for Unclassified Scientific and Technical Reports.

NASA - Leave blank.

NTIS - Leave blank.

Block 13. Abstract. Include a brief (*Maximum 200 words*) factual summary of the most significant information contained in the report.

Block 14. Subject Terms. Keywords or phrases identifying major subjects in the report.

Block 15. Number of Pages. Enter the total number of pages.

Block 16. Price Code. Enter appropriate price code (*NTIS only*).

Blocks 17. - 19. Security Classifications. Self-explanatory. Enter U.S. Security Classification in accordance with U.S. Security Regulations (i.e., UNCLASSIFIED). If form contains classified information, stamp classification on the top and bottom of the page.

Block 20. Limitation of Abstract. This block must be completed to assign a limitation to the abstract. Enter either UL (unlimited) or SAR (same as report). An entry in this block is necessary if the abstract is to be limited. If blank, the abstract is assumed to be unlimited.

FINAL REPORT

GRANT#: N00014-93-1-0380

R&T CODE: 341u011

PRINCIPAL INVESTIGATOR: Peter G. Schultz

INSTITUTION: University of California, Berkeley

GRANT TITLE: Novel Biopolymeric Materials

AWARD PERIOD: 1 March 1993 - 28 February 1996

OBJECTIVE: (i) To design, synthesize and characterize new classes of biopolymers with novel physical, conformational or biological properties; (ii) To develop a new framework, relative to the antibody molecule, for the selective binding of molecules and (iii) To initiate a program for the combinatorial synthesis and evaluation of large libraries of solid state materials for novel electronic, magnetic and optical properties.

APPROACH AND ACCOMPLISHMENTS:

(i) A Combinatorial Approach to Materials Discovery

A method that combines thin film deposition and physical masking techniques has been used for the parallel synthesis of spatially addressable libraries of solid state materials. Arrays containing different combinations, stoichiometries and deposition sequences of BaCO₃, Bi₂O₃, CaO, CuO, PbO, SrCO₃ and Y₂O₃ were generated using a series of binary masks. The arrays were sintered and BiSrCaCuO and YBaCuO superconducting films were identified. Samples down to 200 μm x 200 μm in size were generated, corresponding to library densities of 10,000 sites/inch². The ability to generate and screen combinatorial libraries of solid state compounds, when coupled with theory and empirical observations, may significantly increase the rate at which novel electronic, magnetic and optical materials are discovered and theoretical predictions tested.

(ii) The Solid Phase Synthesis of *N*-Alkylcarbamate Oligomers

An efficient method for the solid phase synthesis of *N*-alkylcarbamate oligomers from alternating carboxylic acid and *N*^α-Fmoc protected chiral *p*-nitrophenylcarbonate monomers has been developed. The general synthetic scheme involves four steps per coupling cycle: deprotection of the terminal amino group of the growing oligomer, acylation of the free amine with a carboxylic acid monomer, reduction of the resulting amide bond with borane and coupling of the secondary amine to a *N*^α-Fmoc protected *p*-nitrophenyl carbonate monomer. This novel biopolymer which has two side chain residues per backbone carbamate linkage and no backbone hydrogen bond donors may provide new frameworks for drug design as well as folded domains with novel physical and biological properties.

(iii) The Solid Phase Synthesis of Oligoureas

An efficient method for solid phase synthesis of oligoureas from readily prepared optically active azido 4-nitrophenyl carbamate monomers is described.

(iv) Synthesis of a Cyclic Urea as a Nonnatural Biopolymer Scaffold

A cyclic urea trimer was synthesized from readily available amino acid derivatives using a simple, iterative approach. A selective amide reduction using borane (BH₃-THF) and a triphosgene-mediated cyclization are the key features in a synthesis of the cyclic urea trimer **2**.

(v) Novel Biopolymers for Drug Discovery

The natural biopolymers, oligopeptides, nucleic acids and oligosaccharides, have evolved to carry out specific cellular functions such as biocatalysis, signal transduction, and information storage. Chemistry and molecular biology have significantly advanced our ability to synthesize and manipulate the structures of these molecules. However, the question arises whether we can design whole new classes of "synthetic biopolymers" with properties or functions not found in the natural biopolymers. One such opportunity may be in the search for new therapeutic agents.

(vi) An Unnatural Biopolymer for Drug Discovery

In an effort to determine whether "unnatural" polymeric backbones exist with improved pharmacological properties relative to those of peptides, we have developed a highly efficient method for the solid phase synthesis of oligocarbamates and oligocarbamate libraries. Oligocarbamates were synthesized from a pool of optically active, *N*-protected aminocarbonate monomers with greater than 99% overall coupling efficiencies. A spatially defined library of oligocarbamates was generated using photochemical methods and screened for binding affinity to a monoclonal antibody. A number of high affinity ligands were then synthesized and analyzed in solution with respect to their IC₅₀ values, water/octanol partitioning coefficients, and proteolytic stability. The synthesis and characterization of these and other unnatural polymers may not only facilitate the development of new drugs, they may also provide new frameworks for testing theories of protein/peptide folding and structure.

CONCLUSIONS: Efficient synthetic methods have been generated for the (i) synthesis of libraries of unnatural oligomers, (ii) methods have been developed for the generation and screening of libraries of electronic, magnetic and optical materials, (iii) miniantibodies have been generated which share some of the properties of antibodies themselves.

SIGNIFICANCE: (i) The above work may provide new classes of unnatural biopolymers with improved properties relative to polypeptides for molecular recognition and catalysis; (ii) Combinatorial methods should increase the rate at which new materials are discovered and our ability to test and refine theory.

AWARD INFORMATION: Harrison Howe Lectureship Award, Rochester Section of the American Chemical Society (1993); National Academy of Sciences, USA (1993); Wolf Prize in Chemistry (1994); Honorary Doctor of Sciences, Uppsala University of Sweden (1994); California Scientist of the Year Award (1995); Discover Magazine Awards for Technological Innovation (1996).

PUBLICATIONS AND REPORTS:

1. Xiang, X.-D.; Sun, X.; Briceño, G.; Lou, Y.; Wang, K.-A.; Chang, H.; Wallace-Freedman, W.G.; Chen, S.-W.; Schultz, P.G. "A Combinatorial Approach to Materials Discovery" *Science* **1995**, *268*, 1738-1740.

2. Paikoff, S.J.; Wilson, T.E.; Cho, C.Y.; Schultz, P.G. "The Solid Phase Synthesis of N-Alkylcarbamate Oligomers" *Tetrahedron Letters* in press
3. Kim, J.-M.; Paikoff, S.J.; Schultz, P.G. "The Solid Phase Synthesis of Oligoureas" *Tetrahedron Letters* in press.
4. Kim, J.-M.; Wilson, T.E.; Norman, T.C.; Schultz, P.G. "Synthesis of a Cyclic Urea as a Nonnatural Biopolymer Scaffold" *Tetrahedron Letters* in press.
5. Moran, E.J.; Wilson, T.E.; Cho, C.Y.; Cherry, S.R.; Schultz, P.G. "Novel Biopolymers for Drug Discovery" *Peptide Science* **1995**, *37*, 213-219.
6. Cho, C.Y.; Moran, E.J.; Cherry, S.; Stephans, J.; Fodor, S.P.A.; Adams, C.; Sundaram, A.; Jacobs, J.W.; Schultz, P.G. "An Unnatural Biopolymer" *Science* **1993**, *261*, 1303-1305.